Eli Lilly Positions Retatrutide as Versatile Workhorse Beyond Bariatric Surgery Alternative, Sees Orals Unlocking Billion-Patient Market
Goldman Sachs 47th Annual Global Healthcare Conference, June 9, 2026
Eli Lilly executives laid out an expansive vision for obesity treatment at Goldman Sachs' healthcare conference today, notably repositioning retatrutide from a niche high-efficacy option into a potential workhorse therapy across broad patient populations. The company's multi-pronged approach spanning injectables, orals, and novel mechanisms now targets what executives describe as a billion-patient opportunity, with current treatments penetrating just 3% of the addressable market.
Retatrutide's Commercial Scope Expands Beyond Initial Positioning
The most significant development concerns how Lilly now views retatrutide's commercial positioning. While the molecule delivers up to 30.3% weight loss at 104 weeks on the highest dose—approaching bariatric surgery efficacy—EVP Kenneth Custer emphasized that the 4-milligram dose presents an equally compelling story. At this lower dose, patients achieved 19% weight loss with just a single titration step and discontinued due to adverse events at a rate nominally lower than placebo.
This finding fundamentally alters the drug's commercial trajectory. Rather than serving exclusively as a next-generation option for patients inadequately served by existing therapies, retatrutide could function across multiple patient segments. "I think reta can fill a lot of spaces in the treatment of overweight and obesity going forward," Custer stated, describing its range from "Zepbound-like efficacy at the 4-milligram dose" to approaching 30% weight loss at higher doses.
When pressed on whether retatrutide would cannibalize the tirzepatide franchise, Custer reframed the question entirely. "If you go back to the idea that we're sort of serving like 3% of the total addressable market right now with these obesity medicines, probably fixating on cannibalization is probably not as productive as thinking about how we unlock the remaining 97%," he said. The executive envisions retatrutide creating an "unlock on top of the franchise" rather than substituting for existing products, suggesting Lilly aims to be a comprehensive weight loss partner where patients might simply be "taking Lilly for overweight obesity" rather than specific branded products.
The TRIUMPH-1 and TRANSCEND-T2D-1 Phase III data presented at ADA reinforce retatrutide's versatility. Beyond weight loss, the molecule delivered 73% reductions in osteoarthritis knee pain and more than 60% reduction in obstructive sleep apnea events. In diabetes, it achieved 2% HbA1c lowering as monotherapy with 17% weight reduction, "moving the goalpost on weight loss in diabetes," according to Custer. Cardiovascular markers including LDL-C, non-HDL cholesterol, C-reactive protein, and blood pressure all moved favorably, though definitive cardiovascular outcomes await the TRIUMPH-3 safety readout later this year and the full TRIUMPH cardiovascular outcomes trial.
Manufacturing Strategy Accommodates Portfolio Flexibility
Lilly has committed over $50 billion to manufacturing since 2020, with significant portions dedicated to incretin medicines. Critically, the company confirmed that retatrutide, tirzepatide, and eloralintide will be produced on common platforms. "Our goal is to forecast the aggregate injectable incretin market to make sure we build for the total, but we can tolerate fluctuations between the molecules within that stack," Custer explained. This fungibility addresses investor concerns about capacity constraints as multiple products scale simultaneously, though the company provided no specific volume guidance.
Eloralintide Emerges as Potential Platform Beyond GI-Intolerant Patients
Lilly's long-acting amylin analog eloralintide is rapidly evolving into what Custer described as potentially "one of the largest development programs in Lilly's history." Phase II data showed 17% weight loss at the titrated 3, 6, and 9-milligram doses with only 2% vomiting rate—what Custer characterized as "incretin-like efficacy with placebo-like tolerability."
The development strategy extends well beyond serving the 5-10% of patients who discontinue GLP-1s due to gastrointestinal adverse events. Lilly is simultaneously pursuing eloralintide as monotherapy, as add-on therapy for patients on incretins who haven't reached goal, and for unspecified new indications where amylin might outperform incretins. "There's even some new indication ideas with Amylin where it might work better than incretins," Custer teased, declining to elaborate.
The Phase IIb combination study of eloralintide with tirzepatide reached primary completion this month, with data expected later in 2026. Custer framed the combination as potentially offering "a very physiological way to drive weight loss" by "lightly agonizing three pathways rather than blasting one." He suggested GIP, GLP-1, and amylin represent "maybe ultimately the three best nutrient-stimulated hormones to put together into a medicine," positioning the combination as both an option for earlier patients and a means to drive substantial weight loss through triple agonism.
From a commercial perspective, the tolerability profile could prove decisive. When asked what weight loss threshold would differentiate eloralintide, Custer indicated that "high teens" weight loss as monotherapy with clear GI tolerability differentiation would constitute "a meaningful medicine," with different benchmarks applying to combination use cases.
Foundayo Launch Progressing Through Staged Commercial Activation
Mike Czapar provided the most detailed Foundayo launch update since approval in April 2026. The company initiated field promotion in April, began sampling in May to drive physician experience with new starts, and launched its first direct-to-consumer advertising during last night's NBA game. Access milestones include coverage across all three pharmacy benefit managers beginning in June and inclusion in the Medicare GLP bridge program effective July 1.
Czapar characterized the launch as "tracking" through its planned sequence, though provided no quantitative metrics. The staged approach reflects the reality that "two months ago, this medicine had zero unaided or aided awareness because nobody knew what Foundayo was," according to Custer. Reception from the healthcare community has been "very positive" as the company now activates consumer-facing channels.
Beyond the initial obesity indication from ATTAIN and ACHIEVE trials, Lilly is investing substantially in Foundayo's development breadth. The company recently shared data supporting its use as maintenance therapy after weight loss on Wegovy or Zepbound. At ADA, Lilly presented three Phase III diabetes studies showing Foundayo performed comparably to comparators on both HbA1c lowering and weight.
The development program extends into multiple cardiometabolic and related conditions: obstructive sleep apnea, osteoarthritis knee pain, peripheral artery disease, stress urinary incontinence, and hypertension, with "more things coming." The ATTAIN cardiovascular outcomes study has been initiated, representing a substantial long-term investment in the asset's profile.
Oral GLP-1s Positioned as Scalability Solution for Global Penetration
Custer provided the most detailed articulation yet of why Lilly views oral GLP-1s as essential to achieving meaningful global penetration. In the United States, approximately three-quarters of patients starting oral GLP-1s are new to the incretin category, validating the hypothesis that "there were a lot of people waiting for something like this." International markets, particularly in Asia, show even higher interest in oral formulations.
The scalability advantages extend beyond patient preference. "These small molecule non-peptide oral GLP-1s, our production capacity is long term, like theoretically infinite on these molecules because they use the same technology as a statin or a blood pressure pill," Custer explained. Unlike peptide injectables, oral GLP-1s leverage existing chemical synthesis infrastructure at Lilly and abundant third-party capacity. They also eliminate cold chain requirements for storage and distribution.
This positions orals as the pathway to developing markets. "As you think about trying to contemplate positively affecting the health of hundreds of millions or even one billion people with incretins, I think this is the only way you get there," Custer stated. The company declined to specify an expected volume split between injectables and orals, noting the market remains in "early innings," but the strategic framing suggests orals could ultimately represent the majority of volume as the market matures globally.
International Mounjaro Momentum Driven by Cash-Pay Willingness
Czapar revealed that approximately 75% of international Mounjaro sales are cash-pay, demonstrating "high willingness to pay" and confirming substantial unmet need outside the United States. Lilly has achieved greater than 50% aggregate international Mounjaro market share, a threshold first crossed late last year. The company now has global launch completion for Mounjaro across key markets including China, Brazil, Mexico, and Korea, all contributing meaningfully to first-quarter growth.
For Foundayo internationally, Lilly submitted in more than 45 countries, predominantly in fourth-quarter 2025, suggesting substantial launch activity beginning late 2026 into 2027. Notably, the company will "launch in all those countries as soon as we have regulatory approval" without gating, positioning Lilly to be first-to-market with an oral GLP-1 in many territories. UAE approval came 24 hours after U.S. approval, with launch already completed there.
Long-Acting Strategy Remains Under Wraps With Multiple Competing Efforts
When pressed on Lilly's ultra-long-acting incretin strategy, including the Camurus collaboration announced approximately one year ago, Custer confirmed the company sees a role for less frequent dosing but provided minimal specifics. "I do strongly believe that molecular properties matter, and I'm not keen to take a weekly drug and overdose it in a way that I might get some partial coverage at the end of a month," he stated, effectively ruling out high-dose tirzepatide as the path to monthly dosing.
Instead, Lilly appears to be running multiple parallel efforts using different time-extension technologies, potentially including excipient-based or prodrug approaches. Custer acknowledged this "bake-off" strategy explicitly: "Lilly sometimes takes the strategy of baking off multiple competing efforts" with the expectation of terminating some programs to "pick the best one." The company declined to provide timelines for disclosure, maintaining that "we do keep our cards a little bit close to our chest on some of these things."
Gene Editing and Portfolio Diversification Funded by Obesity Cash Flows
Beyond incretin-based obesity therapies, Custer emphasized that obesity-driven cash flows are funding substantial diversification efforts. Lilly recently shared Phase I data for VERVE-102, a PCSK9 gene editor that would provide permanent LDL reduction through a single infusion. The therapy effectively converts patients to carriers of naturally occurring loss-of-function PCSK9 mutations associated with lower cardiovascular events. "Patients are getting dramatic reductions in LDL. It may be that you only have to take this therapy once in your life and you have an LDL of 40 mg per deciliter," Custer explained.
The gene editing development pathway could progress from familial hypercholesterolemia to secondary prevention post-myocardial infarction and potentially to primary prevention. Custer framed this as part of Lilly's broader belief in nucleic acid-based therapies and genetic medicines, stating it's "hard for us to imagine a future where ultra-long-acting or durable or even lifelong treatments aren't part of medicine, not just in specialty, but even in more prevalent conditions."
Business development activity continues at an approximately one-deal-per-nine-days pace, with recent announcements including three infectious disease transactions marking Lilly's official reentry into that therapeutic area, the Centessa acquisition for sleep disorders, cardiovascular additions, and in vivo CAR-T technology. In oncology, the company highlighted momentum for Jaypirca with continuing indication expansions, the upcoming olomorasib launch, and the EMBER-4 oral SERD readout that could move the molecule into adjuvant settings. Czapar noted the oncology pipeline now encompasses approximately eight different opportunities with some level of clinical validation.
The conference presentation reinforced that Lilly views its current obesity leadership as a platform for funding and incubating "more provocative ideas for how we could transform health care in very different ways," with diversification efforts extending well beyond the cardiometabolic franchise that currently drives growth.